Now showing items 1155-1174 of 3376

    • Feasibility of using ultrasound for real-time tracking during radiotherapy. 

      Hsu, A; Miller, NR; Evans, PM; Bamber, JC; Webb, S (2005-06)
      This study was designed to examine the feasibility of utilizing transabdominal ultrasound for real-time monitoring of target motion during a radiotherapy fraction. A clinical Acuson 128/XP ultrasound scanner was used to ...
    • Feasibility study of combined dynamic imaging and lymphaticovenous anastomosis surgery for breast cancer-related lymphoedema. 

      Khan, AA; Hernan, I; Adamthwaite, JA; Ramsey, KWD (2019-01)
      BACKGROUND:Breast cancer-related lymphoedema (BCRL) presents a significant healthcare burden and adversely affects quality of life of breast cancer survivors. A prospective feasibility study was performed on lymphaticovenous ...
    • Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development 

      Stratton, M (2008-04)
      We have developed a nonheuristic genome topography scan (GTS) algorithm to characterize the patterns of genomic alterations in human glioblastoma (GBM), identifying frequent p18(INK4C) and p16(INK4A) codeletion. Functional ...
    • Fever of Unknown Origin: the Value of FDG-PET/CT. 

      Kouijzer, IJE; Mulders-Manders, CM; Bleeker-Rovers, CP; Oyen, WJG (2018-03)
      Fever of unknown origin (FUO) is commonly defined as fever higher than 38.3°C on several occasions during at least 3 weeks with uncertain diagnosis after a number of obligatory investigations. The differential diagnosis ...
    • FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment. 

      Wilkins, A; Chauhan, R; Rust, A; Pearson, A; Daley, F; Manodoro, F; Fenwick, K; Bliss, J; Yarnold, J; Somaiah, N (2018-08)
      BACKGROUND:Bio-banked formalin-fixed paraffin-embedded (FFPE) tissues provide an excellent opportunity for translational genomic research. Historically matched blood has not always been collected as a source of germline ...
    • Fibroblastic Reticular Cells Control Conduit Matrix Deposition during Lymph Node Expansion. 

      Martinez, VG; Pankova, V; Krasny, L; Singh, T; Makris, S; White, IJ; Benjamin, AC; Dertschnig, S; Horsnell, HL; Kriston-Vizi, J; Burden, JJ; Huang, PH; Tape, CJ; Acton, SE (2019-11)
      Lymph nodes (LNs) act as filters, constantly sampling peripheral cues. This is facilitated by the conduit network, a tubular structure of aligned extracellular matrix (ECM) fibrils ensheathed by fibroblastic reticular cells ...
    • Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). 

      Darabi, H; Beesley, J; Droit, A; Kar, S; Nord, S; Moradi Marjaneh, M; Soucy, P; Michailidou, K; Ghoussaini, M; Fues Wahl, H; Bolla, MK; Wang, Q; Dennis, J; Alonso, MR; Andrulis, IL; Anton-Culver, H; Arndt, V; Beckmann, MW; Benitez, J; Bogdanova, NV; Bojesen, SE; Brauch, H; Brenner, H; Broeks, A; Brüning, T; Burwinkel, B; Chang-Claude, J; Choi, J-Y; Conroy, DM; Couch, FJ; Cox, A; Cross, SS; Czene, K; Devilee, P; Dörk, T; Easton, DF; Fasching, PA; Figueroa, J; Fletcher, O; Flyger, H; Galle, E; García-Closas, M; Giles, GG; Goldberg, MS; González-Neira, A; Guénel, P; Haiman, CA; Hallberg, E; Hamann, U; Hartman, M; Hollestelle, A; Hopper, JL; Ito, H; Jakubowska, A; Johnson, N; Kang, D; Khan, S; Kosma, V-M; Kriege, M; Kristensen, V; Lambrechts, D; Le Marchand, L; Lee, SC; Lindblom, A; Lophatananon, A; Lubinski, J; Mannermaa, A; Manoukian, S; Margolin, S; Matsuo, K; Mayes, R; McKay, J; Meindl, A; Milne, RL; Muir, K; Neuhausen, SL; Nevanlinna, H; Olswold, C; Orr, N; Peterlongo, P; Pita, G; Pylkäs, K; Rudolph, A; Sangrajrang, S; Sawyer, EJ; Schmidt, MK; Schmutzler, RK; Seynaeve, C; Shah, M; Shen, C-Y; Shu, X-O; Southey, MC; Stram, DO; Surowy, H; Swerdlow, A; Teo, SH; Tessier, DC; Tomlinson, I; Torres, D; Truong, T; Vachon, CM; Vincent, D; Winqvist, R; Wu, AH; Wu, P-E; Yip, CH; Zheng, W; Pharoah, PDP; Hall, P; Edwards, SL; Simard, J; French, JD; Chenevix-Trench, G; Dunning, AM (2016-09-07)
      Genome-wide association studies have found SNPs at 17q22 to be associated with breast cancer risk. To identify potential causal variants related to breast cancer risk, we performed a high resolution fine-mapping analysis ...
    • Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. 

      Dadaev, T; Saunders, EJ; Newcombe, PJ; Anokian, E; Leongamornlert, DA; Brook, MN; Cieza-Borrella, C; Mijuskovic, M; Wakerell, S; Olama, AAA; Schumacher, FR; Berndt, SI; Benlloch, S; Ahmed, M; Goh, C; Sheng, X; Zhang, Z; Muir, K; Govindasami, K; Lophatananon, A; Stevens, VL; Gapstur, SM; Carter, BD; Tangen, CM; Goodman, P; Thompson, IM; Batra, J; Chambers, S; Moya, L; Clements, J; Horvath, L; Tilley, W; Risbridger, G; Gronberg, H; Aly, M; Nordström, T; Pharoah, P; Pashayan, N; Schleutker, J; Tammela, TLJ; Sipeky, C; Auvinen, A; Albanes, D; Weinstein, S; Wolk, A; Hakansson, N; West, C; Dunning, AM; Burnet, N; Mucci, L; Giovannucci, E; Andriole, G; Cussenot, O; Cancel-Tassin, G; Koutros, S; Freeman, LEB; Sorensen, KD; Orntoft, TF; Borre, M; Maehle, L; Grindedal, EM; Neal, DE; Donovan, JL; Hamdy, FC; Martin, RM; Travis, RC; Key, TJ; Hamilton, RJ; Fleshner, NE; Finelli, A; Ingles, SA; Stern, MC; Rosenstein, B; Kerns, S; Ostrer, H; Lu, Y-J; Zhang, H-W; Feng, N; Mao, X; Guo, X; Wang, G; Sun, Z; Giles, GG; Southey, MC; MacInnis, RJ; FitzGerald, LM; Kibel, AS; Drake, BF; Vega, A; Gómez-Caamaño, A; Fachal, L; Szulkin, R; Eklund, M; Kogevinas, M; Llorca, J; Castaño-Vinyals, G; Penney, KL; Stampfer, M; Park, JY; Sellers, TA; Lin, H-Y; Stanford, JL; Cybulski, C; Wokolorczyk, D; Lubinski, J; Ostrander, EA; Geybels, MS; Nordestgaard, BG; Nielsen, SF; Weisher, M; Bisbjerg, R; Røder, MA; Iversen, P; Brenner, H; Cuk, K; Holleczek, B; Maier, C; Luedeke, M; Schnoeller, T; Kim, J; Logothetis, CJ; John, EM; Teixeira, MR; Paulo, P; Cardoso, M; Neuhausen, SL; Steele, L; Ding, YC; De Ruyck, K; De Meerleer, G; Ost, P; Razack, A; Lim, J; Teo, S-H; Lin, DW; Newcomb, LF; Lessel, D; Gamulin, M; Kulis, T; Kaneva, R; Usmani, N; Slavov, C; Mitev, V; Parliament, M; Singhal, S; Claessens, F; Joniau, S; Van den Broeck, T; Larkin, S; Townsend, PA; Aukim-Hastie, C; Gago-Dominguez, M; Castelao, JE; Martinez, ME; Roobol, MJ; Jenster, G; van Schaik, RHN; Menegaux, F; Truong, T; Koudou, YA; Xu, J; Khaw, K-T; Cannon-Albright, L; Pandha, H; Michael, A; Kierzek, A; Thibodeau, SN; McDonnell, SK; Schaid, DJ; Lindstrom, S; Turman, C; Ma, J; Hunter, DJ; Riboli, E; Siddiq, A; Canzian, F; Kolonel, LN; Le Marchand, L; Hoover, RN; Machiela, MJ; Kraft, P; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Freedman, M; Wiklund, F; Chanock, S; Henderson, BE; Easton, DF; Haiman, CA; Eeles, RA; Conti, DV; Kote-Jarai, Z (2018-06-11)
      Prostate cancer is a polygenic disease with a large heritable component. A number of common, low-penetrance prostate cancer risk loci have been identified through GWAS. Here we apply the Bayesian multivariate variable ...
    • Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. 

      Horne, HN; Chung, CC; Zhang, H; Yu, K; Prokunina-Olsson, L; Michailidou, K; Bolla, MK; Wang, Q; Dennis, J; Hopper, JL; Southey, MC; Schmidt, MK; Broeks, A; Muir, K; Lophatananon, A; Fasching, PA; Beckmann, MW; Fletcher, O; Johnson, N; Sawyer, EJ; Tomlinson, I; Burwinkel, B; Marme, F; Guénel, P; Truong, T; Bojesen, SE; Flyger, H; Benitez, J; González-Neira, A; Anton-Culver, H; Neuhausen, SL; Brenner, H; Arndt, V; Meindl, A; Schmutzler, RK; Brauch, H; Hamann, U; Nevanlinna, H; Khan, S; Matsuo, K; Iwata, H; Dörk, T; Bogdanova, NV; Lindblom, A; Margolin, S; Mannermaa, A; Kosma, V-M; Chenevix-Trench, G; kConFab/AOCS Investigators; Wu, AH; Ven den Berg, D; Smeets, A; Zhao, H; Chang-Claude, J; Rudolph, A; Radice, P; Barile, M; Couch, FJ; Vachon, C; Giles, GG; Milne, RL; Haiman, CA; Marchand, LL; Goldberg, MS; Teo, SH; Taib, NAM; Kristensen, V; Borresen-Dale, A-L; Zheng, W; Shrubsole, M; Winqvist, R; Jukkola-Vuorinen, A; Andrulis, IL; Knight, JA; Devilee, P; Seynaeve, C; García-Closas, M; Czene, K; Darabi, H; Hollestelle, A; Martens, JWM; Li, J; Lu, W; Shu, X-O; Cox, A; Cross, SS; Blot, W; Cai, Q; Shah, M; Luccarini, C; Baynes, C; Harrington, P; Kang, D; Choi, J-Y; Hartman, M; Chia, KS; Kabisch, M; Torres, D; Jakubowska, A; Lubinski, J; Sangrajrang, S; Brennan, P; Slager, S; Yannoukakos, D; Shen, C-Y; Hou, M-F; Swerdlow, A; Orr, N; Simard, J; Hall, P; Pharoah, PDP; Easton, DF; Chanock, SJ; Dunning, AM; Figueroa, JD (2016-01)
      The Cancer Genetic Markers of Susceptibility genome-wide association study (GWAS) originally identified a single nucleotide polymorphism (SNP) rs11249433 at 1p11.2 associated with breast cancer risk. To fine-map this locus, ...
    • Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. 

      Vigorito, E; Kuchenbaecker, KB; Beesley, J; Adlard, J; Agnarsson, BA; Andrulis, IL; Arun, BK; Barjhoux, L; Belotti, M; Benitez, J; Berger, A; Bojesen, A; Bonanni, B; Brewer, C; Caldes, T; Caligo, MA; Campbell, I; Chan, SB; Claes, KBM; Cohn, DE; Cook, J; Daly, MB; Damiola, F; Davidson, R; Pauw, AD; Delnatte, C; Diez, O; Domchek, SM; Dumont, M; Durda, K; Dworniczak, B; Easton, DF; Eccles, D; Edwinsdotter Ardnor, C; Eeles, R; Ejlertsen, B; Ellis, S; Evans, DG; Feliubadalo, L; Fostira, F; Foulkes, WD; Friedman, E; Frost, D; Gaddam, P; Ganz, PA; Garber, J; Garcia-Barberan, V; Gauthier-Villars, M; Gehrig, A; Gerdes, A-M; Giraud, S; Godwin, AK; Goldgar, DE; Hake, CR; Hansen, TVO; Healey, S; Hodgson, S; Hogervorst, FBL; Houdayer, C; Hulick, PJ; Imyanitov, EN; Isaacs, C; Izatt, L; Izquierdo, A; Jacobs, L; Jakubowska, A; Janavicius, R; Jaworska-Bieniek, K; Jensen, UB; John, EM; Vijai, J; Karlan, BY; Kast, K; KConFab Investigators; Khan, S; Kwong, A; Laitman, Y; Lester, J; Lesueur, F; Liljegren, A; Lubinski, J; Mai, PL; Manoukian, S; Mazoyer, S; Meindl, A; Mensenkamp, AR; Montagna, M; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Niederacher, D; Olah, E; Olopade, OI; Ong, K-R; Osorio, A; Park, SK; Paulsson-Karlsson, Y; Pedersen, IS; Peissel, B; Peterlongo, P; Pfeiler, G; Phelan, CM; Piedmonte, M; Poppe, B; Pujana, MA; Radice, P; Rennert, G; Rodriguez, GC; Rookus, MA; Ross, EA; Schmutzler, RK; Simard, J; Singer, CF; Slavin, TP; Soucy, P; Southey, M; Steinemann, D; Stoppa-Lyonnet, D; Sukiennicki, G; Sutter, C; Szabo, CI; Tea, M-K; Teixeira, MR; Teo, S-H; Terry, MB; Thomassen, M; Tibiletti, MG; Tihomirova, L; Tognazzo, S; van Rensburg, EJ; Varesco, L; Varon-Mateeva, R; Vratimos, A; Weitzel, JN; McGuffog, L; Kirk, J; Toland, AE; Hamann, U; Lindor, N; Ramus, SJ; Greene, MH; Couch, FJ; Offit, K; Pharoah, PDP; Chenevix-Trench, G; Antoniou, AC (2016-01)
      Population-based genome wide association studies have identified a locus at 9p22.2 associated with ovarian cancer risk, which also modifies ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. We conducted fine-scale ...
    • Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. 

      Shi, J; Zhang, Y; Zheng, W; Michailidou, K; Ghoussaini, M; Bolla, MK; Wang, Q; Dennis, J; Lush, M; Milne, RL; Shu, X-O; Beesley, J; Kar, S; Andrulis, IL; Anton-Culver, H; Arndt, V; Beckmann, MW; Zhao, Z; Guo, X; Benitez, J; Beeghly-Fadiel, A; Blot, W; Bogdanova, NV; Bojesen, SE; Brauch, H; Brenner, H; Brinton, L; Broeks, A; Brüning, T; Burwinkel, B; Cai, H; Canisius, S; Chang-Claude, J; Choi, J-Y; Couch, FJ; Cox, A; Cross, SS; Czene, K; Darabi, H; Devilee, P; Droit, A; Dork, T; Fasching, PA; Fletcher, O; Flyger, H; Fostira, F; Gaborieau, V; García-Closas, M; Giles, GG; Mervi Grip; Guenel, P; Haiman, CA; Hamann, U; Hartman, M; Miao, H; Hollestelle, A; Hopper, JL; Hsiung, C-N; kConFab Investigators; Ito, H; Jakubowska, A; Johnson, N; Torres, D; Kabisch, M; Kang, D; Khan, S; Knight, JA; Kosma, V-M; Lambrechts, D; Li, J; Lindblom, A; Lophatananon, A; Lubinski, J; Mannermaa, A; Manoukian, S; Le Marchand, L; Margolin, S; Marme, F; Matsuo, K; McLean, C; Meindl, A; Muir, K; Neuhausen, SL; Nevanlinna, H; Nord, S; Børresen-Dale, A-L; Olson, JE; Orr, N; van den Ouweland, AMW; Peterlongo, P; Putti, TC; Rudolph, A; Sangrajrang, S; Sawyer, EJ; Schmidt, MK; Schmutzler, RK; Shen, C-Y; Hou, M-F; Shrubsole, MJ; Southey, MC; Swerdlow, A; Teo, SH; Thienpont, B; Toland, AE; Tollenaar, RAEM; Tomlinson, I; Truong, T; Tseng, C-C; Wen, W; Winqvist, R; Wu, AH; Yip, CH; Zamora, PM; Zheng, Y; Floris, G; Cheng, C-Y; Hooning, MJ; Martens, JWM; Seynaeve, C; Kristensen, VN; Hall, P; Pharoah, PDP; Simard, J; Chenevix-Trench, G; Dunning, AM; Antoniou, AC; Easton, DF; Cai, Q; Long, J (2016-09)
      Previous genome-wide association studies among women of European ancestry identified two independent breast cancer susceptibility loci represented by single nucleotide polymorphisms (SNPs) rs13281615 and rs11780156 at 8q24. ...
    • First evaluation of the feasibility of MLC tracking using ultrasound motion estimation. 

      Fast, MF; O'Shea, TP; Nill, S; Oelfke, U; Harris, EJ (2016-08)
      To quantify the performance of the Clarity ultrasound (US) imaging system (Elekta AB, Stockholm, Sweden) for real-time dynamic multileaf collimator (MLC) tracking.The Clarity calibration and quality assurance phantom was ...
    • A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. 

      Mateo, J; Olmos, D; Dumez, H; Poondru, S; Samberg, NL; Barr, S; Van Tornout, JM; Jie, F; Sandhu, S; Tan, DS; Moreno, V; LoRusso, PM; Kaye, SB; Schöffski, P (2016-04)
      The kinase activity of mTOR involves 2 multiprotein complexes, (mTORC1-mTORC2). Targeting mTORC1 with rapalogues induces compensatory feedback loops resulting in AKT/ERK activation, which may be abrogated by mTORC2 inhibition. ...
    • First report on the reliability and validity of speech handicap index in native English-speaking patients with head and neck cancer. 

      Dwivedi, RC; St Rose, S; Roe, JWG; Chisholm, E; Elmiyeh, B; Nutting, CM; Clarke, PM; Kerawala, CJ; Rhys-Evans, PH; Harrington, KJ; Kazi, R (2011-03)
      BACKGROUND: Posttreatment speech problems are seen in nearly half of patients with head and neck cancer. Although there are many voice-specific scales, surprisingly there is no speech-specific questionnaire for English-speaking ...
    • A first step towards practical single cell proteomics: a microfluidic antibody capture chip with TIRF detection 

      Salehi-Reyhani, A; Kaplinsky, J; Burgin, E; Novakova, M; deMello, AJ; Templer, RH; Parker, P; Neil, MAA; Ces, O; French, P; Willison, KR; Klug, D (ROYAL SOC CHEMISTRY, 2011)
      We have developed a generic platform to undertake the analysis of protein copy number from single cells. The approach described here is ‘all-optical’ whereby single cells are manipulated into separate analysis chambers ...
    • First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. 

      Sessa, C; Shapiro, GI; Bhalla, KN; Britten, C; Jacks, KS; Mita, M; Papadimitrakopoulou, V; Pluard, T; Samuel, TA; Akimov, M; Quadt, C; Fernandez-Ibarra, C; Lu, H; Bailey, S; Chica, S; Banerji, U (2013-07)
      PURPOSE:A phase I study was conducted with the primary objective of determining the maximum tolerated dose (MTD) of AUY922 in patients with advanced solid tumors. Secondary objectives included characterization of the safety, ...
    • First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors. 

      Shimomura, A; Yamamoto, N; Kondo, S; Fujiwara, Y; Suzuki, S; Yanagitani, N; Horiike, A; Kitazono, S; Ohyanagi, F; Doi, T; Kuboki, Y; Kawazoe, A; Shitara, K; Ohno, I; Banerji, U; Sundar, R; Ohkubo, S; Calleja, EM; Nishio, M (2019-03)
      HSP90 is involved in stability and function of cancer-related proteins. This study was conducted to define the MTD, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor efficacy of TAS-116, a novel class, ...
    • First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. 

      Pollack, SM; Lu, H; Gnjatic, S; Somaiah, N; O'Malley, RB; Jones, RL; Hsu, FJ; Ter Meulen, J (2017-10)
      Effective induction of antitumor T cells is a pivotal goal of cancer immunotherapy. To this end, lentiviral vectors (LV) are uniquely poised to directly prime CD8 T-cell responses via transduction of dendritic cells in ...
    • A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies. 

      Juric, D; de Bono, JS; LoRusso, PM; Nemunaitis, J; Heath, EI; Kwak, EL; Macarulla Mercadé, T; Geuna, E; Jose de Miguel-Luken, M; Patel, C; Kuida, K; Sankoh, S; Westin, EH; Zohren, F; Shou, Y; Tabernero, J (2017-09)
      Purpose: To evaluate the safety, MTD, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of TAK-117 (MLN1117/INK1117), an investigational PI3Kα-selective inhibitor, in patients with advanced solid ...